DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Cilostazol |
DMZMSCT
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Cilostazol. |
Arterial occlusive disease [BD40]
|
[10] |
Linezolid |
DMGFPU2
|
Moderate |
Additive hypotensive effects by the combination of Treprostinil and Linezolid. |
Bacterial infection [1A00-1C4Z]
|
[11] |
Lapatinib |
DM3BH1Y
|
Moderate |
Decreased metabolism of Treprostinil caused by Lapatinib mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[12] |
Trastuzumab Emtansine |
DMU1LXS
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Trastuzumab Emtansine. |
Breast cancer [2C60-2C6Y]
|
[10] |
Pentosan polysulfate |
DM2HRKE
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Pentosan polysulfate. |
Chronic pain [MG30]
|
[13] |
Phenylbutazone |
DMAYL0T
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Phenylbutazone. |
Chronic pain [MG30]
|
[10] |
Ketoprofen |
DMRKXPT
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Ketoprofen. |
Chronic pain [MG30]
|
[10] |
Levomilnacipran |
DMV26S8
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Levomilnacipran. |
Chronic pain [MG30]
|
[14] |
Anisindione |
DM2C48U
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Anisindione. |
Coagulation defect [3B10]
|
[10] |
Regorafenib |
DMHSY1I
|
Major |
Increased risk of bleeding by the combination of Treprostinil and Regorafenib. |
Colorectal cancer [2B91]
|
[15] |
Ardeparin |
DMYRX8B
|
Major |
Increased risk of bleeding by the combination of Treprostinil and Ardeparin. |
Coronary thrombosis [BA43]
|
[16] |
Mifepristone |
DMGZQEF
|
Moderate |
Decreased metabolism of Treprostinil caused by Mifepristone mediated inhibition of CYP450 enzyme. |
Cushing syndrome [5A70]
|
[17] |
Lumacaftor |
DMCLWDJ
|
Moderate |
Increased metabolism of Treprostinil caused by Lumacaftor mediated induction of CYP450 enzyme. |
Cystic fibrosis [CA25]
|
[18] |
MK-8228 |
DMOB58Q
|
Moderate |
Decreased metabolism of Treprostinil caused by MK-8228 mediated inhibition of CYP450 enzyme. |
Cytomegaloviral disease [1D82]
|
[12] |
Danaparoid |
DM6CLBN
|
Major |
Increased risk of bleeding by the combination of Treprostinil and Danaparoid. |
Deep vein thrombosis [BD71]
|
[16] |
Rivaroxaban |
DMQMBZ1
|
Major |
Increased risk of bleeding by the combination of Treprostinil and Rivaroxaban. |
Deep vein thrombosis [BD71]
|
[19] |
Sertraline |
DM0FB1J
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Sertraline. |
Depression [6A70-6A7Z]
|
[14] |
Fluoxetine |
DM3PD2C
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Fluoxetine. |
Depression [6A70-6A7Z]
|
[14] |
Vilazodone |
DM4LECQ
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Vilazodone. |
Depression [6A70-6A7Z]
|
[14] |
Paroxetine |
DM5PVQE
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Paroxetine. |
Depression [6A70-6A7Z]
|
[14] |
Selegiline |
DM6034S
|
Moderate |
Additive hypotensive effects by the combination of Treprostinil and Selegiline. |
Depression [6A70-6A7Z]
|
[11] |
Vortioxetine |
DM6F1PU
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Vortioxetine. |
Depression [6A70-6A7Z]
|
[14] |
Duloxetine |
DM9BI7M
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Duloxetine. |
Depression [6A70-6A7Z]
|
[14] |
Isocarboxazid |
DMAF1NB
|
Moderate |
Additive hypotensive effects by the combination of Treprostinil and Isocarboxazid. |
Depression [6A70-6A7Z]
|
[11] |
Milnacipran |
DMBFE74
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Milnacipran. |
Depression [6A70-6A7Z]
|
[14] |
Escitalopram |
DMFK9HG
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Escitalopram. |
Depression [6A70-6A7Z]
|
[14] |
Tranylcypromine |
DMGB5RE
|
Moderate |
Additive hypotensive effects by the combination of Treprostinil and Tranylcypromine. |
Depression [6A70-6A7Z]
|
[11] |
Desvenlafaxine |
DMHD4PE
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Desvenlafaxine. |
Depression [6A70-6A7Z]
|
[14] |
Phenelzine |
DMHIDUE
|
Moderate |
Additive hypotensive effects by the combination of Treprostinil and Phenelzine. |
Depression [6A70-6A7Z]
|
[11] |
Clomipramine |
DMINRKW
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Clomipramine. |
Depression [6A70-6A7Z]
|
[14] |
Heme |
DMGC287
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Heme. |
Discovery agent [N.A.]
|
[20] |
Apigenin |
DMI3491
|
Minor |
Increased risk of bleeding by the combination of Treprostinil and Apigenin. |
Discovery agent [N.A.]
|
[21] |
PMID28870136-Compound-49 |
DMTUC9E
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and PMID28870136-Compound-49. |
Discovery agent [N.A.]
|
[10] |
Fenfluramine |
DM0762O
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Fenfluramine. |
Epilepsy/seizure [8A61-8A6Z]
|
[14] |
Phenobarbital |
DMXZOCG
|
Moderate |
Increased metabolism of Treprostinil caused by Phenobarbital mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[22] |
Carbamazepine |
DMZOLBI
|
Moderate |
Increased metabolism of Treprostinil caused by Carbamazepine mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[22] |
Mefenamic acid |
DMK7HFI
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Mefenamic acid. |
Female pelvic pain [GA34]
|
[10] |
Ripretinib |
DM958QB
|
Moderate |
Decreased metabolism of Treprostinil caused by Ripretinib mediated inhibition of CYP450 enzyme. |
Gastrointestinal stromal tumour [2B5B]
|
[12] |
Avapritinib |
DMK2GZX
|
Major |
Increased risk of bleeding by the combination of Treprostinil and Avapritinib. |
Gastrointestinal stromal tumour [2B5B]
|
[15] |
Sulfinpyrazone |
DMEV954
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Sulfinpyrazone. |
Gout [FA25]
|
[10] |
Rifampin |
DMA8J1G
|
Moderate |
Increased metabolism of Treprostinil caused by Rifampin mediated induction of CYP450 enzyme. |
HIV-infected patients with tuberculosis [1B10-1B14]
|
[23] |
Rifapentine |
DMCHV4I
|
Moderate |
Increased metabolism of Treprostinil caused by Rifapentine mediated induction of CYP450 enzyme. |
HIV-infected patients with tuberculosis [1B10-1B14]
|
[22] |
Tipranavir |
DM8HJX6
|
Major |
Increased risk of bleeding by the combination of Treprostinil and Tipranavir. |
Human immunodeficiency virus disease [1C60-1C62]
|
[24] |
Gemfibrozil |
DMD8Q3J
|
Moderate |
Decreased metabolism of Treprostinil caused by Gemfibrozil mediated inhibition of CYP450 enzyme. |
Hyper-lipoproteinaemia [5C80]
|
[12] |
Teriflunomide |
DMQ2FKJ
|
Moderate |
Decreased metabolism of Treprostinil caused by Teriflunomide mediated inhibition of CYP450 enzyme. |
Hyper-lipoproteinaemia [5C80]
|
[12] |
Dipyridamole |
DMXY30O
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Dipyridamole. |
Hypertension [BA00-BA04]
|
[10] |
Meclofenamic acid |
DM05FXR
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Meclofenamic acid. |
Inflammatory spondyloarthritis [FA92]
|
[10] |
Acalabrutinib |
DM7GCVW
|
Major |
Increased risk of bleeding by the combination of Treprostinil and Acalabrutinib. |
Mature B-cell lymphoma [2A85]
|
[25] |
Ibrutinib |
DMHZCPO
|
Major |
Increased risk of bleeding by the combination of Treprostinil and Ibrutinib. |
Mature B-cell lymphoma [2A85]
|
[22] |
Ponatinib |
DMYGJQO
|
Major |
Increased risk of bleeding by the combination of Treprostinil and Ponatinib. |
Mature B-cell lymphoma [2A85]
|
[26] |
Vemurafenib |
DM62UG5
|
Moderate |
Decreased metabolism of Treprostinil caused by Vemurafenib mediated inhibition of CYP450 enzyme. |
Melanoma [2C30]
|
[12] |
Dabrafenib |
DMX6OE3
|
Moderate |
Increased metabolism of Treprostinil caused by Dabrafenib mediated induction of CYP450 enzyme. |
Melanoma [2C30]
|
[22] |
Panobinostat |
DM58WKG
|
Major |
Increased risk of bleeding by the combination of Treprostinil and Panobinostat. |
Multiple myeloma [2A83]
|
[27] |
Ozanimod |
DMT6AM2
|
Moderate |
Additive hypotensive effects by the combination of Treprostinil and Ozanimod. |
Multiple sclerosis [8A40]
|
[11] |
Fedratinib |
DM4ZBK6
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Fedratinib. |
Myeloproliferative neoplasm [2A20]
|
[10] |
Dasatinib |
DMJV2EK
|
Major |
Increased risk of bleeding by the combination of Treprostinil and Dasatinib. |
Myeloproliferative neoplasm [2A20]
|
[28] |
Omacetaxine mepesuccinate |
DMPU2WX
|
Major |
Increased risk of bleeding by the combination of Treprostinil and Omacetaxine mepesuccinate. |
Myeloproliferative neoplasm [2A20]
|
[13] |
Prasugrel |
DM7MT6E
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Prasugrel. |
Myocardial infarction [BA41-BA43]
|
[10] |
Vorapaxar |
DMA16BR
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Vorapaxar. |
Myocardial infarction [BA41-BA43]
|
[10] |
Tirofiban |
DMQG17S
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Tirofiban. |
Myocardial infarction [BA41-BA43]
|
[10] |
Sibutramine |
DMFJTDI
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Sibutramine. |
Obesity [5B80-5B81]
|
[14] |
Dexfenfluramine |
DMJ7YDS
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Dexfenfluramine. |
Obesity [5B80-5B81]
|
[14] |
Diclofenac |
DMPIHLS
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Diclofenac. |
Osteoarthritis [FA00-FA05]
|
[10] |
Nepafenac |
DMYK490
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Nepafenac. |
Osteoarthritis [FA00-FA05]
|
[29] |
Naproxen |
DMZ5RGV
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Naproxen. |
Osteoarthritis [FA00-FA05]
|
[10] |
MK-4827 |
DMLYGH4
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and MK-4827. |
Ovarian cancer [2C73]
|
[15] |
Aspirin |
DM672AH
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Aspirin. |
Pain [MG30-MG3Z]
|
[10] |
Etodolac |
DM6WJO9
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Etodolac. |
Pain [MG30-MG3Z]
|
[10] |
Ibuprofen |
DM8VCBE
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Ibuprofen. |
Pain [MG30-MG3Z]
|
[10] |
Nabumetone |
DMAT2XH
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Nabumetone. |
Pain [MG30-MG3Z]
|
[10] |
Piroxicam |
DMTK234
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Piroxicam. |
Pain [MG30-MG3Z]
|
[10] |
Safinamide |
DM0YWJC
|
Moderate |
Additive hypotensive effects by the combination of Treprostinil and Safinamide. |
Parkinsonism [8A00]
|
[11] |
Rasagiline |
DM3WKQ4
|
Moderate |
Additive hypotensive effects by the combination of Treprostinil and Rasagiline. |
Parkinsonism [8A00]
|
[11] |
Choline salicylate |
DM8P137
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Choline salicylate. |
Postoperative inflammation [1A00-CA43]
|
[10] |
Ketorolac |
DMI4EL5
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Ketorolac. |
Postoperative inflammation [1A00-CA43]
|
[10] |
Bromfenac |
DMKB79O
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Bromfenac. |
Postoperative inflammation [1A00-CA43]
|
[10] |
ABIRATERONE |
DM8V75C
|
Moderate |
Decreased metabolism of Treprostinil caused by ABIRATERONE mediated inhibition of CYP450 enzyme. |
Prostate cancer [2C82]
|
[12] |
Sorafenib |
DMS8IFC
|
Moderate |
Decreased metabolism of Treprostinil caused by Sorafenib mediated inhibition of CYP450 enzyme. |
Renal cell carcinoma [2C90]
|
[12] |
Salsalate |
DM13P4C
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Salsalate. |
Rheumatoid arthritis [FA20]
|
[10] |
Meloxicam |
DM2AR7L
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Meloxicam. |
Rheumatoid arthritis [FA20]
|
[10] |
Sulindac |
DM2QHZU
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Sulindac. |
Rheumatoid arthritis [FA20]
|
[10] |
Oxaprozin |
DM9UB0P
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Oxaprozin. |
Rheumatoid arthritis [FA20]
|
[10] |
Flurbiprofen |
DMGN4BY
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Flurbiprofen. |
Rheumatoid arthritis [FA20]
|
[10] |
Fenoprofen |
DML5VQ0
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Fenoprofen. |
Rheumatoid arthritis [FA20]
|
[10] |
Tolmetin |
DMWUIJE
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Tolmetin. |
Rheumatoid arthritis [FA20]
|
[10] |
Salicyclic acid |
DM2F8XZ
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Salicyclic acid. |
Seborrhoeic dermatitis [EA81]
|
[10] |
Warfarin |
DMJYCVW
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Warfarin. |
Supraventricular tachyarrhythmia [BC81]
|
[10] |
Plicamycin |
DM7C8YV
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Plicamycin. |
Testicular cancer [2C80]
|
[10] |
Caplacizumab |
DMPUKA7
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Caplacizumab. |
Thrombocytopenia [3B64]
|
[10] |
Apixaban |
DM89JLN
|
Major |
Increased risk of bleeding by the combination of Treprostinil and Apixaban. |
Thrombosis [DB61-GB90]
|
[15] |
Cangrelor |
DM8JRH0
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Cangrelor. |
Thrombosis [DB61-GB90]
|
[10] |
Brilinta |
DMBR01X
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Brilinta. |
Thrombosis [DB61-GB90]
|
[15] |
Clopidogrel |
DMOL54H
|
Moderate |
Increased risk of bleeding by the combination of Treprostinil and Clopidogrel. |
Thrombosis [DB61-GB90]
|
[10] |
Cabozantinib |
DMIYDT4
|
Major |
Increased risk of bleeding by the combination of Treprostinil and Cabozantinib. |
Thyroid cancer [2D10]
|
[30] |
Trimethoprim |
DMM7CHK
|
Moderate |
Decreased metabolism of Treprostinil caused by Trimethoprim mediated inhibition of CYP450 enzyme. |
Urinary tract infection [GC08]
|
[12] |
Betrixaban |
DM2C4RF
|
Major |
Increased risk of bleeding by the combination of Treprostinil and Betrixaban. |
Venous thromboembolism [BD72]
|
[31] |
----------- |
|
|
|
|
|